Kim, Anthony J.
Adjunct Professor, Fischell Department of Bioengineering
Research Health Scientist, U.S. Department of Veterans Affairs
Co-Director, Translational Therapeutics Research Group
University of Maryland School of Medicine
Education and Training
B.S., Chemical Engineering, Pennsylvania State University, 2001
Ph.D., Chemical and Biomolecular Engineering, University of Pennsylvania, 2006
Postdoctoral Fellow, University of Pennsylvania, 2007-2009
Postdoctoral Fellow, Johns Hopkins University School of Medicine, 2009-2013
Selected Honors and Awards
VA Merit Review Award, 2022
Maryland Innovation Initiative Award, 2019
Accelerated Translational Project Award, Institute for Clinical and Translational Research, 2019
NIH MERIT Award (R37), 2018
Collaborative MPI Program Award, University of Maryland Greenebaum Comprehensive Cancer Center (UMGCCC), 2017
NIH K25 Quantitative Research Career Development Award, 2014-2017
AAPS New Investigator Award, American Association of Pharmaceutical Scientists, 2015
Genentech/AAPS Innovation in Biotechnology Award, 2015
PhRMA Foundation Research Starter Grant in Pharmaceutics, 2014
NIH F32 NRSA individual Postdoctoral Fellowship, 2011-2013
Wilmer Research Award, 2012
As Director of the Nanotherapeutics Laboratory and Co-Director of the Translational Therapeutics Research Group (TTRG), Dr. Kim's research focuses on developing translational nanomedicine for brain, breast, and other cancers. This is achieved through a collaborative team of engineers, basic scientists, and clinicians to spur innovation at the interface of bioengineering and clinical medicine. Towards this goal, his team will (1) identify and characterize the rate-limiting extra- and intracellular barriers by applying innovative biophysical tools and (2) develop advanced therapeutic platforms that overcome these barriers to improve therapeutic outcomes. Dr. Kim has authored more than 55 peer-reviewed papers, including publications in Science, Nature Materials, ACS Nano, Science Advances, Journal of the American Chemical Society, Angewandte Chemie, Physical Review Letters, and Biomaterials. His research program has been supported by the National Institutes of Health (NIH), U.S. Department of Veterans Affairs (VA), National Science Foundation (NSF), American Cancer Society (ACS), Elsa U. Pardee Foundation, AAPS Foundation, PhRMA Foundation, TEDCO, FUS Foundation, and others.
NIH R01 CA269995 (Role: MPI), 12/01/22 - 11/31/27
Nanotherapeutic enhancement of interstitial thermal therapy for glioblastoma
VA I01 BX005770 (Role: PI), 07/01/22 – 06/31/26
Novel drug delivery strategies for treatment of breast cancer brain metastases
NIH R37 CA218617 (Role: PI), 03/01/18 – 02/28/25
Impact of Fn14-targeted Nanoparticles for Triple-Negative Breast Cancer
UMB/UMCP Neuro-Link Research Project (Role: MPI), 01/15/22 – 01/15/25
Advancing Laser Interstitial Thermal Therapy for Glioblastoma using Plasmonic Nanoparticles
NIH R01 NS107813 (Role: Co-I), 04/01/19 – 03/31/24
Nanotherapeutic treatment of the invasive glioblastoma microenvironment
Focused Ultrasound Foundation Research Project (Role: Co-I), 06/01/22 – 05/31/23
PET-labeling and Testing of Paclitaxel Nanoformulations with MB-FUS
BIOE447 & BIOE489O: Clinical Experiences in Bioengineering Course, Brain Drug Delivery/Neurosurgery, University of Maryland A. James Clark School of Engineering, 2021, 2022, 2023
GPLS 665 Cancer Biology: From Basic Research to the Clinic, Drug Delivery/Targeting, University of Maryland Graduate School, 2020, 2021, 2022
MSTP Molecules to Medicine (M2M) Course, Nanotechnology for Drug Delivery, University of Maryland School of Medicine, 2021
CIPP 907: Conflicts of Interest in Biomedical Research course, University of Maryland Graduate School, 2015 - present
Carney CP*, Pandey N*, Kapur A, Saadi H, Ong HL, Chen C, Winkles JA, Woodworth GF, Kim AJ. (2023) Impact of targeting moiety type and protein corona formation on the uptake of Fn14-targeted nanoparticles by cancer cells. ACS Nano. 17, 19667
Pandey N, Anastasiadisa P, Carney CP, Kanvinde P, Woodworth GF, Winkles JA, Kim AJ. (2022) Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment. Advanced Drug Delivery Reviews. 188, 114415.
Dancy JG*, Wadajkar AS*, Connolly NP, Galisteo R, Ames HM, Peng S, Tran NL, Goloubeva OG, Woodworth GF, Winkles JA, Kim AJ. (2020) Decreased nonspecific adhesivity, receptor-targeted therapeutic nanoparticles for primary and metastatic breast cancer. Science Advances. 6, eaax393.
Wadajkar AS, Dancy JG, Roberts NR, Connolly N, Strickland DK, Winkles JA, Woodworth GF, Kim AJ. (2017) Decreased non-specific adhesivity, receptor targeted (DART) nanoparticles exhibit improved dispersion, cellular uptake, and tumor retention in invasive gliomas. Journal of Controlled Release 267, 144.
Schneider CS, Perez JG, Cheng E, Zhang C, Panagiotis M, Hanes J, Winkles JA, Woodworth GF, Kim AJ. (2015) Minimizing the Non-specific Binding of Nanoparticles to the Brain Enables Active Targeting of Fn14-positive Glioblastoma Cells. Biomaterials. 42, 42.
Kim AJ, Boylan NJ, Suk JS, Hwangbo M, Yu T, Shuster BS, Cebotaru L, Lesniak, WG, Oh JS, Adstamongkonkul P, Choi AY, Kannan RM, Hanes J. (2013) Use of Single-Site Functional PEG-Dendrons to Prepare Gene Vectors that Penetrate Human Mucus Barriers. Angewandte Chemie Int Ed. 52, 3985.
Kim AJ, Scarlett R, Biancaniello PL, Sinno TR, Crocker JC. (2009) Probing interfacial equilibration in microsphere crystals formed by DNA-directed assembly. Nature Materials. 8, 52.
Kim AJ, Manoharan VN, Crocker JC. (2005) Swelling-Based Method for Preparing Stable, Functionalized Polymer Colloids. Journal of the American Chemical Society. 127, 1592.
Find a complete list of Dr. Kim's publications on his Google Scholar Page